Search results
Found 8461 matches for
Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.
Andrea Soult
Andrea Soult - Research Pharmacist
Thitthiphone Olinh
Thitthiphone Olinh - Research Pharmacist
Nicholas White
COVID-19 Investigators Principal Investigators Research Scientists
FRS Nicholas White - Professor of Tropical Medicine
Naomi Waithira
COVID-19 Investigators Graduate Students Research Scientists
Naomi Waithira - MORU head of Data Management